240 related articles for article (PubMed ID: 24174331)
1. Molecular dynamics study of HIV-1 RT-DNA-nevirapine complexes explains NNRTI inhibition and resistance by connection mutations.
Vijayan RS; Arnold E; Das K
Proteins; 2014 May; 82(5):815-29. PubMed ID: 24174331
[TBL] [Abstract][Full Text] [Related]
2. The N348I mutation at the connection subdomain of HIV-1 reverse transcriptase decreases binding to nevirapine.
Schuckmann MM; Marchand B; Hachiya A; Kodama EN; Kirby KA; Singh K; Sarafianos SG
J Biol Chem; 2010 Dec; 285(49):38700-9. PubMed ID: 20876531
[TBL] [Abstract][Full Text] [Related]
3. Compensatory role of double mutation N348I/M184V on nevirapine binding landscape: insight from molecular dynamics simulation.
Karubiu W; Bhakat S; Soliman ME
Protein J; 2014 Oct; 33(5):432-46. PubMed ID: 25107349
[TBL] [Abstract][Full Text] [Related]
4. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.
Yap SH; Sheen CW; Fahey J; Zanin M; Tyssen D; Lima VD; Wynhoven B; Kuiper M; Sluis-Cremer N; Harrigan PR; Tachedjian G
PLoS Med; 2007 Dec; 4(12):e335. PubMed ID: 18052601
[TBL] [Abstract][Full Text] [Related]
5. Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
Gupta S; Fransen S; Paxinos EE; Stawiski E; Huang W; Petropoulos CJ
Antimicrob Agents Chemother; 2010 May; 54(5):1973-80. PubMed ID: 20194692
[TBL] [Abstract][Full Text] [Related]
6. N348I in HIV-1 reverse transcriptase can counteract the nevirapine-mediated bias toward RNase H cleavage during plus-strand initiation.
Biondi MJ; Beilhartz GL; McCormick S; Götte M
J Biol Chem; 2010 Aug; 285(35):26966-26975. PubMed ID: 20530477
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 reverse transcriptase connection subdomain mutations involved in resistance to approved non-nucleoside inhibitors.
Menéndez-Arias L; Betancor G; Matamoros T
Antiviral Res; 2011 Nov; 92(2):139-49. PubMed ID: 21896288
[TBL] [Abstract][Full Text] [Related]
8. A novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.
Nikolenko GN; Delviks-Frankenberry KA; Pathak VK
J Virol; 2010 May; 84(10):5238-49. PubMed ID: 20219933
[TBL] [Abstract][Full Text] [Related]
9. Structural insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138.
Ren J; Nichols CE; Stamp A; Chamberlain PP; Ferris R; Weaver KL; Short SA; Stammers DK
FEBS J; 2006 Aug; 273(16):3850-60. PubMed ID: 16911530
[TBL] [Abstract][Full Text] [Related]
10. Application of Structure-based Methods to Analyze Resistance Mutations for Chemically Diverse Non-Nucleoside Reverse Transcriptase Inhibitors.
Tabassum T; Azeem SM; Muwonge AN; Frey KM
Curr HIV Res; 2020; 18(4):283-291. PubMed ID: 32493197
[TBL] [Abstract][Full Text] [Related]
11. Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.
Hachiya A; Kodama EN; Sarafianos SG; Schuckmann MM; Sakagami Y; Matsuoka M; Takiguchi M; Gatanaga H; Oka S
J Virol; 2008 Apr; 82(7):3261-70. PubMed ID: 18216099
[TBL] [Abstract][Full Text] [Related]
12. Effects of HIV-1 reverse transcriptase connection subdomain mutations on polypurine tract removal and initiation of (+)-strand DNA synthesis.
Betancor G; Álvarez M; Marcelli B; Andrés C; Martínez MA; Menéndez-Arias L
Nucleic Acids Res; 2015 Feb; 43(4):2259-70. PubMed ID: 25662223
[TBL] [Abstract][Full Text] [Related]
13. The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity.
Xu HT; Colby-Germinario SP; Oliveira M; Han Y; Quan Y; Zanichelli V; Wainberg MA
J Virol; 2014 Feb; 88(3):1536-47. PubMed ID: 24227862
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 reverse transcriptase (RT) polymorphism 172K suppresses the effect of clinically relevant drug resistance mutations to both nucleoside and non-nucleoside RT inhibitors.
Hachiya A; Marchand B; Kirby KA; Michailidis E; Tu X; Palczewski K; Ong YT; Li Z; Griffin DT; Schuckmann MM; Tanuma J; Oka S; Singh K; Kodama EN; Sarafianos SG
J Biol Chem; 2012 Aug; 287(35):29988-99. PubMed ID: 22761416
[TBL] [Abstract][Full Text] [Related]
15. A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy.
Paredes R; Puertas MC; Bannister W; Kisic M; Cozzi-Lepri A; Pou C; Bellido R; Betancor G; Bogner J; Gargalianos P; Bánhegyi D; Clotet B; Lundgren J; Menéndez-Arias L; Martinez-Picado J;
J Infect Dis; 2011 Sep; 204(5):741-52. PubMed ID: 21844300
[TBL] [Abstract][Full Text] [Related]
16. Effect of a bound non-nucleoside RT inhibitor on the dynamics of wild-type and mutant HIV-1 reverse transcriptase.
Zhou Z; Madrid M; Evanseck JD; Madura JD
J Am Chem Soc; 2005 Dec; 127(49):17253-60. PubMed ID: 16332074
[TBL] [Abstract][Full Text] [Related]
17. Effect of translocation defective reverse transcriptase inhibitors on the activity of N348I, a connection subdomain drug resistant HIV-1 reverse transcriptase mutant.
Michailidis E; Singh K; Ryan EM; Hachiya A; Ong YT; Kirby KA; Marchand B; Kodama EN; Mitsuya H; Parniak MA; Sarafianos SG
Cell Mol Biol (Noisy-le-grand); 2012 Dec; 58(1):187-95. PubMed ID: 23273211
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 reverse transcriptase and antiviral drug resistance. Part 2.
Das K; Arnold E
Curr Opin Virol; 2013 Apr; 3(2):119-28. PubMed ID: 23602470
[TBL] [Abstract][Full Text] [Related]
19. Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
Balzarini J
Curr Top Med Chem; 2004; 4(9):921-44. PubMed ID: 15134549
[TBL] [Abstract][Full Text] [Related]
20. A polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activity.
Wright DW; Deuzing IP; Flandre P; van den Eede P; Govaert M; Setiawan L; Coveney PV; Marcelin AG; Calvez V; Boucher CA; Beerens N
PLoS One; 2013; 8(10):e74078. PubMed ID: 24098331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
